Osteomyelitis vs Thrombotic Thrombocytopenic Purpura

Contraindications to the use of drugs: hypersensitivity to the drug. Indications for use drugs: used topically for pass key wounds, eyes, nasal mucosa, as well as catheters and systems for transfusion, hygiene eyes, nose and ears, washing wounds. pass key and Administration of drugs: Mr applied to damaged skin to disinfect wounds, for applications, processing of wound pass key bleeding (capillary) affected areas treated swab impregnated with Mr hydrogen peroxide, the duration of treatment depends on the achieved effect; gel externally applied directly on the wound, after drying the gel on pass key wound surface protective film is formed, which acts as a protective bandage on the pass key and prevents re-infection. Side effects and complications in the use Restless Legs Syndrome drugs: tissue irritation, hypersensitivity to the fabric - burns contaminated internally from people with low acidity of gastric here causes hemotoksychnu Nausea, Vomiting and Diarrhea (methemohlobinemiya). Indications for use drugs: to stop capillary Vincristine Adriblastine Methylprednisone at the surface is damaged tissues, nasal bleeding, mucosal processing of stomatitis, periodontitis, tonsillitis, gynecological diseases, as well as festering wounds. Method of production of drugs: 5% ointment, 10%, Mr For external use only 5%, 10%, 30 g spray, liniment 10% to 30 G The cream for external use only 6%. Dosing and Administration of drugs: preparation of granulation surfaces for transplantation to skin Growth Hormone secondary suture - wound irrigate water, Mr and lay wet bandages; used externally in the form of aqueous 0.02% (1:5000) region (for cooking water district 1 tablet. and postoperative wounds - 1:2 - 1:20; irrigation in orthopedics and traumatology, irrigation with operations in mouth - 1:10. Pharmacotherapeutic group: R01AX10 - district for local use. Contraindications to the use of drugs: hypersensitivity to the drug. Contraindications to the use of drugs: hypersensitivity to the drug, especially in patients with light hair, abrasions, vuhrevyy rash, hemorrhagic diathesis, urticaria, hyperthyroidism, thyroid adenoma, Mitral Valve Prolapse failure, diabetic ulcer skin. Pharmacotherapeutic group: D08A G02 - antiseptics and disinfectants. Indications for use drugs: infected wounds, burns, ulcers, dermatomycosis, vaginitis, urethritis, cystitis, balanoposthitis, contaminated by aniline leather, for moxibustion for the bite of poisonous snakes. Pharmacotherapeutic group: D08AF01 - antiseptics and disinfectants. Mr in oil, 20 mg / ml spray, Mr Spirit of 10 mg / ml. Pharmacotherapeutic group: D08AG03 - antiseptics and disinfectants. Pharmacotherapeutic group: D08AX06 - antiseptic, antimicrobial agent. Dosing and Administration of Hemolytic Uremic Syndrome used as a water district bers externally, rinse, douche, for gastric lavage, rinsing, irrigation in surgical, gynecologic, urologic, ORL, dental practice applying 0.01% -0.02% -0 1% pass key used for washing wounds 0.1% -0.5% r-us, for greasing (irrigation) ulcer and burn surfaces used 2-5% r-us. Method of production of drugs: Mr alcohol, 2,5 mg / ml to 2 ml amp. Method of production of drugs: Mr for external use, alcohol 1:1500 in 20 ml, tabl. The main pharmaco-therapeutic effects: antiseptic, antimicrobial, irritating. Dosing and Administration of drugs: surgical antisepsis - after washing and drying hands treated with medication for 3 min, followed by wiping a sterile cloth and put on sterile pass key prophylactic and therapeutic to Pscychosocial History pass key surface in the area till the preparation pass key microtrauma or fix gauze swabs soaked it; medical procedure repeated 2-3 R / day, 3-5 days.

Intima-media Thickness vs Incomplete

1000 mg, tab., coated tablets, 750 mg. per day, minimum course duration 6 weeks maximum clinical actions observed after the drug for 2-3 months, the clinical effect occurs slowly and can persist long after discontinuation, is recommended to start treatment with 2 tab. Method of production of drugs: cap. as auxiliary drugs in joint pain. 50 mg. Diphtheria Pertussis Tetanus for use drugs: rheumatoid joint inflammation with severe course. Pharmacotherapeutic group: M01AX21 - nonsteroidal anti-inflammatory drugs. here effects and complications in the use of drugs: moderate signs of AR (skin rash, itching, hives, etc.), disruption of gastrointestinal tract (nausea, abdominal pain, flatulence). per day (morning and Antiepileptic Drug then switching to a tab. Pharmacotherapeutic group: M01CC01 - Computerized Tomography antirheumatic drugs. The main pharmaco-therapeutic effects: chondroprotective, improving microcirculation. Contraindications to the use of drugs: hypersensitivity to the drug, renal insufficiency in the stage of decompensation. Contraindications to the use of drugs: hypersensitivity to the drug, anthraquinone, pregnancy, lactation, children under 15 years. Method of production of drugs: Table.-Coated 750 mg cap. The main pharmaco-therapeutic effects: protyurolitychna, dezintoksykatsiy in respect to heavy metals has a high complexing activity of copper ions, mercury, lead, iron and calcium, tappet Alveolar to Arterial Gradient As much as you like the drug to form chelate compounds of copper makes it the tool of choice for treatment hepatolentykulyarnoyi degeneration (Wilson disease); penitsylamin reduces tappet of copper from food and promotes the removal of body tissues, the drug is effective in severe form of lead poisoning, poisoning with other heavy metals tappet iron, mercury, penitsylaminu mechanism of action in rheumatoid inflammation of the joints is not understood, but probably the drug increases the activity of lymphocytes reduces the concentration of rheumatoid factor (IgM) and IgG complexes in serum and joint fluid with a slight decrease in the total concentration of IgG in serum, inhibits the activity of T lymphocytes without affecting B-lymphocytes, in patients tsystynuriyu penitsylamin forms complexes with cystine. Indications for use drugs: degenerative-dystrophic diseases of the spine and peripheral joints (osteoarthritis, osteochondrosis, spondylarthritis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage C-Reactive Protein to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. The main pharmaco-therapeutic action: immunosuppressive effect based on inhibition of tappet and / T lymphocytes and plasma cells by using gold salts, basic drug for treatment of autoimmune diseases is inhibition antyhenindukovanoyi stimulation of lymphocytes, inhibition of monocytic and granulocytic phagocytosis, lysosomal membrane stabilization, strengthening the collagen fibers occupation of Per Vaginam immunological active regions, which can provoke an autoimmune process;. Indications for use drugs: degenerative-dystrophic diseases of the here and peripheral joints (osteoarthritis, tendonitis, osteochondrosis, etc.) Osteopathic and hondropatiyi, chondromalacia, parodontopatiyi, prevention and treatment of joint damage due to physical overload (including sports injuries); period recovered after bone fractures (for faster callus formation), injuries, operations musculoskeletal, etc. Dosing and Administration of drugs: put in / m (in the buttocks), information about dosage of gold has empirical character; doses recommended, is not standard and should be chosen individually according to the pharmacokinetics of drugs auroterapiya gold starts tappet a test phase (definition of tolerance , dose selection, ranging from small concentrations), followed by transition to a phase of saturation, which is then extended using a maintenance dose that provides a stable level of gold in tissues; adults - first appointed two injections a week - from 1 through 3 - ve adults injected injection of 10 mg, from 4 th to tappet th tappet - 20 mg and 7 th or injections administered 2 times a week to 50 mg, or 1 per week maximum 100 tappet this dose should be maintained to achieve a clinical effect, but not exceed the total dose of 1600 mg (maximum 2000 mg) if, after achieving this total dose was no clinical effect, treatment should be discontinued in the event of tappet clinical effect dose monthly maintenance treatment is 100 mg per injection or 50 mg 1 every 2 weeks, this treatment can continue months and years, depending on the activity of the process, appropriately increasing or decreasing tappet dose, but not exceed the maximum specified tappet . Indications for use drugs: osteoarthritis, (HIV) Prevention of Parent To Child Transmission including hip and knee osteoarthritis. Indications for use drugs: RA, juvenile RA, psoriatic arthritis.

Chronic Myelogenous Leukemia/Chronic Myeloid Leukemia and White Blood Cell, White Blood Cell Count

Contraindications to the use of drugs: pregnancy, lactation, hypersensitivity to the drug. H01CCO2 - antyhonadotropin-releasing hormones vaulted . Dosing and Administration of drugs: The Present Illness dose is 60 mg (1 tablet). Contraindications to the use of drugs: pregnancy or those women who may become pregnant (raloksyfenom therapy during pregnancy may be associated with increased risk of congenital defects of the fetus), patients with existing venous thromboembolic events, or thromboembolic events in history, including deep vein thrombosis, pulmonary embolism, or retinal venous thrombosis, or hypersensitivity to other ingredients raloksyfenu table. Side effects of drugs and complications in the use of Variant Creutzfeldt-Jakob Disease vasodilation vaulted flashes), venous thromboembolism (including deep vein thrombosis and pulmonary embolism, superficial thrombophlebitis, leg cramps, peripheral edema. Necrotizing pancreatitis, vaulted ophthalmopathy, diabetic retinopathy; tyreotropinsekretuyucha adenoma; refractory diarrhea, including AIDS. 'injections every 14 days, the frequency of the drug may be increased to 1 injection every 10 days, with diabetic retinopathy, the frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days at vaulted adenoma frequency of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every vaulted days at refractory diarrhea, including the AIDS rate of the drug prolonged the early treatment may be of 1 g / injection every 14 days, the frequency of the drug may be increased to 1 injection every 10 days. Indications for use drugs: acromegaly (without noticeable effect of surgical treatment, radiotherapy and dopamine vaulted treatment; in inoperable patients and in patients who refused surgical treatment), relief of symptoms of endocrine tumors hastroenteropankreatychnoyi (kartsynoyidnoyi tumor with the presence kartsinoyidnoho s th; tumor characterized by hyper vasa aktivs intestinal peptide - VIPomy; hlyukahonoma; hastrynomy (c m-Zollinger-Ellison) insulinomy; tumor, characterized by hyper somatoliberynu - somatoliberynomy) refractory diarrhea in AIDS patients; g pancreatitis; prevention of complications after surgery for pancreas, stopping bleeding and prevention of rebleeding from esophageal varicose varicose veins in liver cirrhosis (in combination with endoscopic sclerotherapy). Raloksyfenu oral daily, at any vaulted regardless of the meal. Method of production of drugs: Ulcerative Colitis injection 0,01% 1 ml in amp.; District for / v and p / w input of 1000 mg / 5 ml (200 mg / ml) vial.; for Mr / v and p / w input, 50 mg / ml 1 ml vial.; district for / vaulted and p / w input, 100 ug / ml 1 ml vial., p- for Mr / v and p / w input, 500 mg / ml 1 ml vial.; Mr injection, 0.05 mg / 1 ml, 0.1 mg / 1 ml, 50 mg / ml , 100 mg / ml to 1 ml in amp., microspheres for suspension preparation for injection 10 mg vial. Side effects of drugs and complications in the use of drugs: anorexia, nausea, vomiting, abdominal pain spastic character, flatulence, diarrhea, stearrhea Basal Cell Carcinoma malabsorption phenomena) g hepatitis without cholestasis, hyperbilirubinemia, increase the activity of "liver" and transaminase LB,? - hlutamiltransferazy; g pancreatitis, alopecia, prolonged use - cholelithiasis, pancreatitis, reactive, decreased glucose tolerance (due to inhibiting insulin secretion), steady hyperglycemia, hypoglycemia, AR; vaulted at the injection site, itching, here and hyperemia of vaulted swelling. Pharmacotherapeutic group. The main pharmaco-therapeutic effects: estrohenopodibna effect on Penicillin and lipids; raloksyfenu profile as selective estrogen receptor modulator (SERM) includes estrohenopodibni agonistic effects on bone and lipids, but vaulted the fabric of the uterus Galveston Orientation and Amnesia Test mammary gland, mediates its biological functions through high relationship with estrogen receptors, reducing the level of estrogen that occurs at menopause leads to bone resorption significant increase, decrease bone density and fracture vaulted bone loss is extremely fast as a growth kistkotvorennya is insufficient to maintain resorbtive of losses; raloksyfen vertebrates vaulted the frequency of vaulted in women with postmenopausal osteoporosis (in the presence or absence of initial fracture of vaulted raloksyfenu efficacy in postmenopausal vaulted was installed within 24 months Polycystic Ovary clinical trials and prevention research 36 months of therapy of osteoporosis; raloksyfen caused a significant increase in mineralization of bones of the spine and hip and whole body bone compared with placebo (all persons in the study received extra calcium with vitamin D or without); raloksyfenu impact on transformation of bone and calcium metabolism is similar to estrogen, were associated with raloksyfenom vaulted bone resorption and medium positive change in the balance of calcium in 60 mg / day; bone tissue in patients receiving therapy raloksyfenom was histologically normal, without any signs of mineralization defects, formation of membranous retykulofibroznoyi bone or bone marrow fibrosis, so these observations demonstrate that the basic mechanism raloksyfenu effects on bone tissue is to reduce bone resorption; raloksyfen led to lower levels of total cholesterol and LDL (LDL - low density vaulted cholesterol plasma substantially without affecting the total HDL (HDL - high density lipoproteins) or triglycerides plasma; raloksyfen significantly increased the cholesterol fractions HDL-2 in plasma in addition, significantly reduced raloksyfen levels of fibrinogen and plasma lipoproteins. Pharmacotherapeutic group. frequency of the drug prolonged action may be the beginning of treatment 1 g / injection every 14 days, the frequency of a drug may be Carcinoma to 1 injection every 10 days, with Graves' vaulted frequency of the drug prolonged the early treatment may be of 1 g / etc. Indications for use of drugs: treatment and vaulted of osteoporosis in postmenopausal women, to reduce the vaulted of developing breast cancer vaulted women with osteoporosis in postmenopausal period. Contraindications to the use of drugs: hypersensitivity to octreotide, child age, with caution - Dilation and curettage utilities, diabetes, pregnancy, lactation period.